Pfizer (PFE) AGM 2025 summary

Opening remarks and agenda

• The meeting was opened by the Corporate Secretary, with the CEO and Inspectors of Election present; forward-looking statements and risk factors were referenced.

• The agenda included financial and operational updates, voting on five proposals, and a Q&A session with shareholders.

Financial performance review

• Achieved $4.5 billion in expected net cost savings by end of 2025 through cost realignment.

• Returned $9.5 billion to shareholders via dividends, invested nearly $11 billion in R&D, and paid down $7.8 billion in debt in 2024.

• Strong commercial performance in the U.S. and internationally, with continued demand for key products like Nurtec and Vyndaqel.

• AI initiatives delivered over $700 million in annual operating savings, targeting $2 billion impact by 2026.

Board and executive committee updates

• Two new board members, Tim Buckley and Cyrus Taraporevala, joined, bringing expertise in governance and financial markets.

• All 13 current directors were nominated for reelection for one-year terms.